Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Relapsed Multiple Myeloma Undergoing Chemotherapy

Inclusion Criteria

• Participants must have histologically confirmed multiple myeloma that is relapsed or refractory
• Participants must have a diagnosis of relapsed multiple myeloma according to standard criteria established by the International Myeloma Working Group
• Platelet count > 50,000/mm^3 and < 100,000/mm^3 within 14 days prior to study entry
• Patients may have had 1 or more prior chemotherapy regimens for multiple myeloma but none within the preceding 14 days
• Performance status (Eastern Cooperative Oncology Group [ECOG]) =< 2
• Total bilirubin =< 1.5 mg/dL
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
• Creatinine =< 3mg/dL
• Ability to understand and the willingness to sign a written informed consent document
• The effects of eltrombopag on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
• Subjects must be willing to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

• Participants with a history of pelvic irradiation; or chemotherapy or radiotherapy within the preceding 14 days
• Participants may not be receiving any other study agents within 21 days prior to entry on the study
• The use of growth factors other than erythropoiesis stimulating agents or G-CSF (filgrastim) (Neupogen or Neulasta) during the study period
• Participants with evidence of active thromboembolic disease or a history of thromboembolism within the preceding 6 months (excluding thrombosis of a central line)
• Participants with a documented history of genetic predisposition for thrombosis (anti-phospholipid antibody syndrome, antithrombin [AT]-III deficiency, etc.), platelet disorder or bleeding disorder
• Pregnant or lactating women
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Individuals with a history of other malignancies are eligible only if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; individuals with the following cancers are eligible if diagnosed and treated within the preceding 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
• Participants with an absolute neutrophil count (ANC) < 500